Novavax, Inc. (NVAX): Price and Financial Metrics

Novavax, Inc. (NVAX): $7.19

0.08 (+1.13%)

POWR Rating

Component Grades








Add NVAX to Watchlist
Sign Up

Industry: Biotech




#74 of 359

in industry

NVAX Price/Volume Stats

Current price $7.19 52-week high $25.66
Prev. close $7.11 52-week low $5.61
Day low $7.03 Volume 4,110,600
Day high $7.38 Avg. volume 7,245,537
50-day MA $7.95 Dividend yield N/A
200-day MA $8.63 Market Cap 678.76M

NVAX Stock Price Chart Interactive Chart >


  • NVAX scores best on the Value dimension, with a Value rank ahead of 91.89% of US stocks.
  • The strongest trend for NVAX is in Growth, which has been heading up over the past 177 days.
  • NVAX ranks lowest in Stability; there it ranks in the 0th percentile.

NVAX Stock Summary

  • NOVAVAX INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 4.42% of US listed stocks.
  • NVAX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 4.45% of US stocks.
  • With a year-over-year growth in debt of -55.63%, NOVAVAX INC's debt growth rate surpasses just 4.76% of about US stocks.
  • Stocks that are quantitatively similar to NVAX, based on their financial statements, market capitalization, and price volatility, are PLX, EXEL, GSIT, MRKR, and BCDA.
  • Visit NVAX's SEC page to see the company's official filings. To visit the company's web site, go to

NVAX Valuation Summary

  • NVAX's price/sales ratio is 0.4; this is 90% lower than that of the median Healthcare stock.
  • NVAX's price/earnings ratio has moved up 8.7 over the prior 243 months.

Below are key valuation metrics over time for NVAX.

Stock Date P/S P/B P/E EV/EBIT
NVAX 2023-09-22 0.4 -0.9 -1.1 -0.6
NVAX 2023-09-21 0.4 -0.9 -1.1 -0.6
NVAX 2023-09-20 0.4 -0.9 -1.1 -0.6
NVAX 2023-09-19 0.5 -1.0 -1.2 -0.7
NVAX 2023-09-18 0.4 -0.9 -1.2 -0.7
NVAX 2023-09-15 0.5 -1.0 -1.2 -0.7

NVAX Growth Metrics

    The 3 year cash and equivalents growth rate now stands at 1390.08%.
  • The 5 year revenue growth rate now stands at 7.39%.
  • Its 4 year net income to common stockholders growth rate is now at 53.22%.
Over the past 34 months, NVAX's revenue has gone up $1,963,815,000.

The table below shows NVAX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 1,981.872 -415.937 -657.939
2022-09-30 1,846.673 -640.529 -1,321.974
2022-06-30 1,290.94 -743.964 -1,475.792
2022-03-31 1,403.032 -428.649 -1,317.624
2021-12-31 1,146.29 322.946 -1,743.751
2021-09-30 1,203.749 536.786 -1,075.031

NVAX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NVAX has a Quality Grade of C, ranking ahead of 58.82% of graded US stocks.
  • NVAX's asset turnover comes in at 0.6 -- ranking 60th of 680 Pharmaceutical Products stocks.
  • GTHX, SRRA, and OPK are the stocks whose asset turnover ratios are most correlated with NVAX.

The table below shows NVAX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.600 1 -14.595
2021-03-31 0.606 1 -1.737
2020-12-31 0.502 1 -0.781
2020-09-30 0.345 1 -0.602
2020-06-30 0.126 1 -0.222
2020-03-31 0.084 1 -0.295

NVAX Price Target

For more insight on analysts targets of NVAX, see our NVAX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $264.20 Average Broker Recommendation 1.58 (Moderate Buy)

Novavax, Inc. (NVAX) Company Bio

Novavax, Inc. focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company was founded in 1987 and is based in Gaithersburg, Maryland.

NVAX Latest News Stream

Event/Time News Detail
Loading, please wait...

NVAX Latest Social Stream

Loading social stream, please wait...

View Full NVAX Social Stream

Latest NVAX News From Around the Web

Below are the latest news stories about NOVAVAX INC that investors may wish to consider to help them evaluate NVAX as an investment opportunity.

New COVID vaccine rollout running into insurance, supply roadblocks

The rollout of new COVID-19 vaccines is being obstructed by insurance and supply roadblocks, as customers experience issues with getting insurers to agree on vaccine coverage. The Department of Health and Human Services wrote a letter to insurers stating, "Your obligation as a plan or issuer to ensure that your members have coverage for COVID-19 vaccines without cost sharing is not conditional upon parties' compliance." Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down the news. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

Yahoo | September 25, 2023

Is Novavax Stock A Sell As The FDA Holds Off On Approving Its Covid Vaccine?

Novavax stock is under pressure after the FDA didn't approve its Covid shot with Pfizer's and Moderna's. Is NVAX stock a buy or a sell today?

Yahoo | September 21, 2023

Does This Message From Moderna Mean Bad News for Novavax?

Moderna (NASDAQ: MRNA) recently gave an update on its pipeline and future goals, and the biotech had a lot to say. This doesn't mean Moderna is forgetting about the coronavirus vaccine though. In fact, this market giant announced something that could impact smaller rival Novavax (NASDAQ: NVAX).

Yahoo | September 21, 2023

Novavax and Invitae implement cost-cutting measures amid financial challenges

In the volatile world of stock trading, healthcare companies Novavax (NASDAQ:NVAX) and Invitae (NYSE:NVTA) have been making headlines as they navigate significant financial challenges. Both firms are taking measures to reduce costs, aiming to improve their financial standing and appeal to a broader range of investors.

Yahoo | September 19, 2023

Moderna (MRNA) Receives CHMP Nod for Updated COVID Vaccine

Clinical data from studies on Moderna's (MRNA) updated COVID vaccine shows improved antibody responses against multiple circulating variants, including BA.2.86, EG.5 and FL.1.5.1 variants.

Yahoo | September 15, 2023

Read More 'NVAX' Stories Here

NVAX Price Returns

1-mo -13.37%
3-mo -3.23%
6-mo 3.75%
1-year -63.34%
3-year -93.53%
5-year -80.88%
YTD -30.06%
2022 -92.81%
2021 28.30%
2020 2,701.76%
2019 -89.18%
2018 48.39%

Continue Researching NVAX

Want to see what other sources are saying about Novavax Inc's financials and stock price? Try the links below:

Novavax Inc (NVAX) Stock Price | Nasdaq
Novavax Inc (NVAX) Stock Quote, History and News - Yahoo Finance
Novavax Inc (NVAX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!